Navigation Links
Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
Date:3/9/2009

Market Vision, Engineering Know-how, and Smart Plastics Expertise Combine

to bring Practical Cell Technologies to the Life Sciences

N. BILLERICA, Mass., March 9 /PRNewswire/ -- Seahorse Bioscience, Inc., manufacturer of instruments and consumables for cell based metabolic assays today announced the acquisition of BioProcessors Corp., manufacturer of systems for optimizing biologic drug manufacturing. The two companies will be integrated and operate under the Seahorse name.

A concurrent $6MM financing included Commonwealth Capital, Oxford Bioscience, Flagship Ventures, Life Sciences Partners, FLIR Systems Inc, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Seahorse applies its expertise in engineering and biology to modernize cell-based science using "smart plastic" consumables and easy to use instruments. Its XF series instruments measure energy consumption and mitochondrial function in cells in a 24 or 96 well microplate with precision and throughput far better than any previous technology. It has enabled new insights into the metabolic deficiencies underlying many neurological diseases, obesity, diabetes, cancer and cardiovascular disease, as well as an early indication of potential toxicities of candidate drug compounds.

The BioProcessors "SimCell" technology modernizes biologic drug manufacturing scale-up and optimization using plastic, microplate-sized cards with six small bioreactors. One technician can run tens, hundreds or even 1,000 simultaneous experiments for weeks or months to select clones, optimize medium, or determine the best process conditions for protein manufacturing. The system offers Biopharmaceutical and CMO customers a strong competitive advantage in developing and optimizing production of biologic products from mammalian cell culture.

"Both the XF and SimCell technologies have reached a key milestone where thought-leading customers have demonstrated their value," said Jay Teich, CEO. "Our sales of XF series instruments tripled in 2008, and we introduced three new products to this market at the end of the year. With the addition of the people and technologies of BioProcessors Corp., we will expand and grow the SimCell product line and markets during the coming year."

"Seahorse hit the nail on the head with its XF96 instrument and their business has grown steadily. We believe that the SimCell technology will fuel continued growth in the years to come," said Jeff Hurst of Commonwealth Capital.

"We have supported BioProcessors through their development and customer validation of the SimCell technology. We now look forward to participating in a strong company with complementary product lines and a growing worldwide market presence," said Fouad Azzam of Life Sciences Partners.

Liberty Tree Advisors, LLC acted as financial advisor to Seahorse Bioscience.

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.

    Media Contact: Cynthia Egan
    Phone: 978.671.1610


'/>"/>
SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
3. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Neogen Acquires Kane Enterprises
6. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
7. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
8. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
9. NSF International Acquires David Begg Associates
10. United BioSource Acquires Caro Research, Leader in Simulation Modeling
11. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):